Details

Autor(en) / Beteiligte

• Parra Salinas, Ingrid
• Bermudez, Aranzazu
• López Corral, Lucia
• Lopez Godino, Oriana
• Móles‐Poveda, Paula
• Martín, Guillermo
• Costilla Barriga, Lissette
• Ferrá Coll, Christelle
• Márquez‐Malaver, Francisco
• Ortí, Guillermo
• Zudaire Ripa, Maria Teresa
• Rifon, Jose
• Martinez, Carmen

Titel

Treatment of steroid‐refractory chronic graft‐versus‐host disease with imatinib: Real‐life experience of the Spanish group of hematopoietic transplantation (GETH)

Ist Teil von

• Clinical transplantation, 2021-05, Vol.35 (5), p.e14255-n/a

Ort / Verlag

Denmark

Erscheinungsjahr

2021

Quelle

Wiley Online Library

Beschreibungen/Notizen

• Treatment of steroid‐refractory chronic graft‐versus‐host disease (cGVHD) is a challenge. Here, we describe a retrospective analysis of 66 patients with steroid‐refractory cGVHD treated with imatinib (starting dose of 100 mg in 70% of patients; maximum dose of 100‐200 mg in 74%). Most patients had multi‐organ involvement (≥2 organs, 83%), with the most affected being skin (85%), oral mucosa (55%), eyes (42%), and lungs (33%). The overall response rate was 41% (21 partial and three complete responses). The organ with the best response rate was the skin (46%), followed by gastrointestinal tract (43%), liver (41%), the oral mucosa (36%), eyes (29%), and lungs (18%). Imatinib led to steroid tapering in 17/38 patients. Twenty‐five (38%) patients experienced imatinib‐related adverse events, comprising extra‐hematologic toxicity (n = 24, 36%) and hematologic toxicity (n = 6, 9%). No cases of grade 4‐5 toxicity were reported. The main causes of imatinib discontinuation were treatment failure (52%) and toxicity (9%). After a median follow‐up of 41 months, the 3‐year overall survival was 81%, with no difference between imatinib responders and non‐responders. These real‐life results show that imatinib is safe and has moderate efficacy in patients with heavily pre‐treated cutaneous sclerotic cGVHD; however, activity against lung cGVHD is very limited.